Mivesta 100 mg & 400 mg; FC tablets
PDF Leaflet Revision Date: 15 August 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Indicated for epilepsy and bipolar disorder.
Dosage (summary)
Adults: Start 25 mg daily, increase as needed. Max 500 mg/day. Children: Dosing based on weight.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; passes into breast milk.
Key Drug Interactions
- Valproate increases lamotrigine levels
- Carbamazepine decreases lamotrigine levels
Contraindications
- Hypersensitivity to lamotrigine
Common side effects
- Skin rash
- Headache
- Dizziness
- Nausea
Counselling Points
- Monitor for rash and flu-like symptoms
- Avoid abrupt withdrawal
- Use caution with hormonal contraceptives
Serious warnings
- Risk of serious skin reactions
- Suicidal ideation
- Aseptic meningitis
Important Disclaimer
The Mivesta 100 mg & 400 mg; FC tablets professional information leaflet below is the property of Eurolab and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
